ReviewObesity science & practice2024

Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysis.

Deep Dutta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.